KIWA Bio-Tech Products Group Reviews a Successful 2016
Jan 04, 2017 13:05 pm UTC| Business
CLAREMONT, Calif., Jan. 04, 2017 -- Kiwa Bio-Tech Products Group Corporation (OTCQB:KWBT) is pleased to announce the successful completion of 2016 business goals. Following the completion of a reorganization at the end...
Jan 04, 2017 13:05 pm UTC| Business
Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is...
Jan 04, 2017 13:05 pm UTC| Business
Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is...
Jan 04, 2017 13:05 pm UTC| Business
Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is...
Jan 04, 2017 13:05 pm UTC| Business
Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is...
Jan 04, 2017 13:05 pm UTC| Business
Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is...
Jan 04, 2017 13:05 pm UTC| Business
SEATTLE, Jan. 04, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the appointment of Marc L. Lesnick, Ph.D., as Senior Vice President, Regulatory Affairs...